Ignite Creation Date:
2024-05-06 @ 12:52 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03868423
Status:
WITHDRAWN
Last Update Posted:
2022-02-18
First Post:
2019-02-04
Brief Title:
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Sponsor:
Sameek Roychowdhury
Organization:
Ohio State University Comprehensive Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Malignant Neoplasm |
| ALK Fusion Protein Expression |
| ALK Gene Amplification |
| ALK Gene Mutation |
| Locally Advanced Malignant Solid Neoplasm |
| Metastatic Malignant Neoplasm in the Brain |
| Metastatic Malignant Neoplasm in the Central Nervous System |
| Metastatic Malignant Solid Neoplasm |
| ROS1 Fusion Positive |
| ROS1 Gene Amplification |
| ROS1 Gene Mutation |
Keywords: